article · JHEP Reports
This study analysed the global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) from 2010 to 2021 across 204 countries, using Global Burden of Disease data. It examined prevalence, incidence, and years lived with disability, considering age, sex, and sociodemographic index. Findings show MASLD is a significant global health concern, with a high overall prevalence. Prevalence peaked in middle age and was highest in Kuwait, Egypt, and Qatar in 2021. China, Sudan, and India experienced the largest increases in prevalence over the study period. The incidence of MASLD was found to peak in countries with moderate sociodemographic indices.
Understanding the global patterns and trends of MASLD is crucial for public health. This research highlights where the disease burden is highest and increasing fastest, enabling policymakers and healthcare providers to develop targeted prevention programmes and allocate resources effectively to address this growing health challenge.
The abstract does not indicate a direct application pathway for commercialisation, nor does it suggest specific products or services. It provides epidemiological data valuable for public health planning and policy development, which could indirectly inform the development of future diagnostic tools, treatments, or preventative health programmes.
AI-generated from the published abstract. Always read the original work before citing.
Background & Aims: This study used the Global Burden of Disease data (2010-2021) to analyze the rates and trends of point prevalence, annual incidence, and years lived with disability (YLDs) for metabolic dysfunction-associated steatotic liver disease (MASLD) in 204 countries. Methods: Total numbers and age-standardized rates per 100,000 population for MASLD prevalence, annual incidence, and YLDs were compared across regions and countries by age, sex, and sociodemographic index (SDI). Smoothing spline models were used to evaluate the relationship between the burden of MASLD and SDI. Estimates were reported with uncertainty intervals (UI). Results: 14,310.6 cases per 100,000 population). Prevalence peaked at ages 45-49 for men and 50-54 for women. Kuwait (32,312.2 cases per 100,000 people; 95% UI: 29,947.1-34,839.0), Egypt (31,668.8 cases per 100,000 people; 95% UI: 29,272.5-34,224.7), and Qatar (31,327.5 cases per 100,000 people; 95% UI: 29,078.5-33,790.9) had the highest prevalence rates in 2021. The largest increases in age-standardized point prevalence estimates from 2010 to 2021 were in China (16.9%, 95% UI 14.7%-18.9%), Sudan (13.3%, 95% UI 9.8%-16.7%) and India (13.2%, 95% UI 12.0%-14.4%). MASLD incidence varied with SDI, peaking at moderate SDI levels. Conclusions: MASLD is a global health concern, with the highest prevalence reported in Kuwait, Egypt, and Qatar. Raising awareness about risk factors and prevention is essential in every country, especially in China, Sudan and India, where disease incidence and prevalence are rapidly increasing. Impact and implications: This research provides a comprehensive analysis of the global burden of MASLD, highlighting its rising prevalence and incidence, particularly in countries with varying sociodemographic indices. The findings are significant for both clinicians and policymakers, as they offer critical insights into the regional disparities in MASLD burden, which can inform targeted prevention and intervention strategies. However, the study's reliance on modeling and available data suggests cautious interpretation, and further research is needed to validate these findings in clinical and real-world settings.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.jhepr.2024.101271
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
